Johnson & Johnson $JNJ Shares Bought by Focus Advisor Solutions LLC

Focus Advisor Solutions LLC increased its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 48.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 70,070 shares of the company’s stock after acquiring an additional 22,901 shares during the period. Focus Advisor Solutions LLC’s holdings in Johnson & Johnson were worth $18,551,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. National Pension Service boosted its position in shares of Johnson & Johnson by 1.3% during the 2nd quarter. National Pension Service now owns 5,226,968 shares of the company’s stock valued at $1,327,493,000 after acquiring an additional 67,484 shares during the last quarter. IFP Advisors Inc grew its holdings in shares of Johnson & Johnson by 8.8% in the second quarter. IFP Advisors Inc now owns 38,760 shares of the company’s stock valued at $9,844,000 after purchasing an additional 3,133 shares during the period. Elefante Mark B grew its holdings in shares of Johnson & Johnson by 9.8% in the second quarter. Elefante Mark B now owns 28,686 shares of the company’s stock valued at $7,285,000 after purchasing an additional 2,563 shares during the period. AMG Asset Management Group Inc. increased its position in Johnson & Johnson by 172.0% during the third quarter. AMG Asset Management Group Inc. now owns 3,852 shares of the company’s stock worth $1,020,000 after purchasing an additional 2,436 shares during the last quarter. Finally, Gradient Investments LLC increased its position in Johnson & Johnson by 9.9% during the second quarter. Gradient Investments LLC now owns 152,831 shares of the company’s stock worth $38,815,000 after purchasing an additional 13,737 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Johnson & Johnson

These are some of the JNJ headlines that stood out recently:

  • Positive Sentiment: J&J plans to acquire Ollin Biosciences, adding a Phase III retinal-disease candidate to its ophthalmology pipeline. Reports cite a $2.2 billion deal, potentially worth up to $3.3 billion; Blackstone is expected to contribute $750 million toward development. UBS sees the asset as a possible growth driver beyond 2030. Article: Planned Ollin acquisition as a growth driver
  • Neutral Sentiment: The reported average analyst price target is $275.92, near the share price cited in the provided market data; the target offers little clear near-term direction on its own. Article: JNJ average price target
  • Negative Sentiment: Shares came under pressure following insider selling, which can raise concerns about executives’ view of near-term prospects, though it does not by itself establish a change in the company’s outlook. Article: JNJ share weakness following insider selling

Analysts Set New Price Targets

A number of brokerages have commented on JNJ. Weiss Ratings downgraded shares of Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a research note on Friday, October 23rd. Sanford C. Bernstein set a $270.00 price target on shares of Johnson & Johnson in a research note on Thursday, October 15th. Bank of America restated a “neutral” rating and set a $278.00 price target on shares of Johnson & Johnson in a report on Tuesday, September 29th. Evercore set a $300.00 price target on shares of Johnson & Johnson in a research report on Tuesday, October 20th. Finally, JPMorgan Chase & Co. upped their price objective on Johnson & Johnson from $270.00 to $285.00 and gave the company a “neutral” rating in a report on Tuesday, September 29th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $275.92.

Get Our Latest Research Report on JNJ

Insider Activity at Johnson & Johnson

In related news, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president owned 25,447 shares in the company, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Elizabeth Forminard sold 13,072 shares of the stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total value of $3,717,546.08. Following the completion of the transaction, the executive vice president directly owned 16,994 shares in the company, valued at $4,832,923.66. This trade represents a 43.48% decrease in their position. The SEC filing for this sale provides additional information. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Trading Down 2.1%

JNJ opened at $272.75 on Thursday. Johnson & Johnson has a 52 week low of $199.38 and a 52 week high of $290.25. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The business has a fifty day simple moving average of $267.42 and a 200-day simple moving average of $250.61. The firm has a market cap of $656.58 billion, a P/E ratio of 26.17, a P/E/G ratio of 2.75 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. During the same period in the prior year, the firm earned $2.80 EPS. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities analysts expect that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be paid a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is presently 81.21%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.